[{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sage Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for SAGE-718

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : SAGE-718 (dalzanemdor) is an oral, first-in-class investigational NMDA receptor positive allosteric modulator. It is being evaluated for treatment of mild cognitive impairment in hunginton’s disease.

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 20, 2024

Lead Product(s) : SAGE-718

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : SAGE-718 (dalzanemdor) is an oral, first-in-class investigational NMDA receptor positive allosteric modulator. It is being evaluated for treatment of mild cognitive impairment in parkinson’s disease.

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 08, 2024

Lead Product(s) : SAGE-718

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : SAGE-718 (dalzanemdor) is an oral, first-in-class investigational NMDA receptor positive allosteric modulator. It is being evaluated for mild cognitive impairment in parkinson’s disease.

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 17, 2024

Lead Product(s) : SAGE-718

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : SAGE-718 is first-in-class NMDA receptor positive allosteric modulator and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including HD, PD...

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 18, 2023

Lead Product(s) : SAGE-718

Therapeutic Area : Genetic Disease

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : SAGE-718 is first-in-class NMDA receptor positive allosteric modulator and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including HD, PD...

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 22, 2023

Lead Product(s) : SAGE-718

Therapeutic Area : Genetic Disease

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Phase 2 LUMINARY Study showed SAGE-718, a positive allosteric modulator of NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with MCI and dementia du...

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 01, 2022

Lead Product(s) : SAGE-718

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The PARADIGM Study is a Phase 2, open-label study evaluating the safety, tolerability, and efficacy of SAGE-718, first-in-class NMDA receptor PAM once daily in individuals with mild cognitive impairment due to Parkinson’s disease.

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 15, 2022

Lead Product(s) : SAGE-718

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : SAGE-718, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease (HD), Parkinson’s disease (PD) and Alzheimer’s disease (AD).

Brand Name : SAGE-718

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 15, 2021

Lead Product(s) : SAGE-718

Therapeutic Area : Genetic Disease

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank